超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

印度制藥公司W(wǎng)ockhardt
Wockhardt Limited India,成立于1960年，印度最大的醫(yī)藥和生物科技企業(yè)，該公司提供包括藥物配方，營(yíng)養(yǎng)素產(chǎn)品和疫苗，活性藥物成份，以及生物制藥等領(lǐng)域的產(chǎn)品和服務(wù)。截止到2005年底該公司共有大約3500名員工，其中大約500名員工供職于海外分支機(jī)構(gòu)。Wockhardt還是印度唯一獲得“超級(jí)品牌”稱號(hào)的醫(yī)藥企業(yè)，該稱號(hào)由國(guó)際組織“超級(jí)品牌理事會(huì)”頒發(fā)。

Wockhardt 和許多重要的制藥公司諸如Aventis, Amylin 以及 Astra Zeneca等組成了戰(zhàn)略聯(lián)盟。它在印度和英國(guó)都有分公司，這些分公司都接受美國(guó)FDA和英國(guó)MHRA的認(rèn)證。

Preparing for change before change beckons. Harnessing the power of innovative research. Providing high-quality medicines for a healthier world. This is our world at Wockhardt.
Wockhardt is a global, pharmaceutical and biotechnology company that has grown by leveraging two powerful trends impacting the world of medicine - globalisation and biotechnology.

The Company has a market capitalisation of over US$ 1 billion and an annual turnover of US$ 650 million. Wockhardt’s pace of growth and momentum permeates every mindset, system and technology within the organisation.

Wockhardt today, is distinguished by a strong and growing presence in the world’s leading markets, with more than 65% of its revenue coming from Europe and the United States. Wockhardt’s market presence covers formulations, biopharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients (APIs).

The Company has its headquarters in India, and has
14 manufacturing plants in India, UK, Ireland, France and US
Subsidiaries in US, UK, Ireland and France
Marketing offices in Africa, Russia, Central and South East Asia.
 

Wockhardt has a strong track record in acquisition management, with five successful acquisitions in the European market. These acquisitions have strengthened Wockhardt’s position in the high-potential markets of Europe, and have expanded the global reach of the organisation.

Wockhardt Advantage

Wockhardt’s manufacturing facilities in India, UK, Ireland, France and US have the approval of major regulatory bodies, including US FDA and UK's MHRA, with capabilities for both Finished Dosage Formulations and APIs. The output includes

Steriles (Injectables)
Biopharmaceuticals
Orals (Tablets & Liquids)
Topicals (Creams & Ointments).

Wockhardt is a partner of choice for manufacturing, having entered into manufacturing alliances with leading pharmaceutical and biotechnology majors, including

Astra Zeneca Lab Aguettant
Aventis Amylin
Schering-Plough Eisai
Cell Therapeutics LSI, UK
AFT, New Zealand Ebewe, Austria

A key growth driver at Wockhardt is its state-of-the-art, multi-disciplinary research capability backed by a team of 500 skilled scientists. Consistent efforts have resulted in six breakthrough biotechnology products, 750+ patent filings and a pipeline of promising new molecules.

Wockhardt’s strategies are aligned towards being a significant player in the emerging global biopharmaceuticals market. In order to achieve this goal, the company has set up the Wockhardt Biotech Park, India’s largest biopharmaceuticals complex, with six dedicated plants built to international standards.